预约演示
更新于：2025-12-27
Diclofenac Diethylamine
双氯芬酸二乙胺
更新于：2025-12-27
概要
基本信息
原研机构- |
在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22Cl2N2O2 |
InChIKeyZQVZPANTCLRASL-UHFFFAOYSA-N |
CAS号78213-16-8 |
关联
61
项与 双氯芬酸二乙胺 相关的临床试验CTR20253705
双氯芬酸二乙胺乳胶剂在健康研究参与者中的生物等效性研究
CTR20253275
随机、开放、单剂量、两制剂、三序列、三周期、半重复交叉对照试验设计，评价中国健康受试者在空腹状态下使用外用制剂双氯芬酸二乙胺乳胶剂的生物等效性正式试验
CTR20252985
双氯芬酸二乙胺乳胶剂在中国健康成年研究参与者中随机、开放、单剂量、四周期、完全重复交叉、空腹状态下的生物等效性试验
100 项与 双氯芬酸二乙胺 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的专利（医药）
登录后查看更多信息
162
项与 双氯芬酸二乙胺 相关的文献（医药）2025-12-01Current Research in Translational Medicine
Green solvent-based synthesis of diclofenac diethylamine-loaded PCL nanoparticles for sustained drug delivery
Article
作者: Ajji, Zaki Ali ; Al-Laham, Antoun ; Soliman, Soolafa Al
BACKGROUND:
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), has demonstrated promising antitumor properties; however, its clinical application is limited by systemic toxicity. Encapsulation in biodegradable polymeric nanoparticles offers a strategy to enhance therapeutic efficacy while minimizing adverse effects. Nevertheless, the use of toxic organic solvents in nanoparticle fabrication remains a significant challenge.
OBJECTIVE:
This study aimed to develop and characterize diclofenac diethylamine-loaded polycaprolactone (PCL) nanoparticles using green solvents and to compare two preparation methods-emulsification solvent evaporation/extraction and spontaneous emulsification solvent diffusion-for producing diclofenac-loaded nanoparticles with potential applications in tumor therapy.
METHODS:
Diclofenac diethylamine-loaded PCL nanoparticles were prepared using both methods, employing a novel green solvent system. The nanoparticles were characterized in terms of size, polydispersity index (PDI), zeta potential, morphology, and encapsulation efficiency. In vitro drug release profiles were evaluated and fitted to kinetic models.
RESULTS:
The developed diclofenac diethylamine-loaded PCL nanoparticles exhibited a mean diameter below 200 nm, a monodisperse population, and a negative surface charge. Both preparation methods achieved high encapsulation efficiency and prolonged, diffusion-controlled drug release. The spontaneous solvent diffusion method provided slightly better control over particle size.
CONCLUSION:
These nanoparticles are well-suited for cancer therapy, offering sustained drug release, enhanced safety due to the use of green solvents, and robust physicochemical stability. The findings support their potential as an innovative, effective, and safe delivery system for antitumoral applications.
2025-09-12Zhongguo zhen jiu = Chinese acupuncture & moxibustion
[Electroacupuncture at neuro-arterial stimulation points for post-stroke shoulder-hand syndrome: a randomized controlled trial].
Article
作者: Zhao, Meidan ; Wu, Jiazhu ; Liu, Zhixin ; Yin, Xiumei ; Xu, Zhifang ; DU, Yuanhao ; Zhang, Man
Objective:
To compare the clinical efficacy of electroacupuncture (EA) at neuro-arterial stimulation points with topical western medication in treating post-stroke shoulder-hand syndrome (SHS).
Methods:
A total of 72 patients with post-stroke SHS were randomly assigned to an observation group (n=36, 2 cases dropped out) and a control group (n=36, 3 cases dropped out). Both groups received standard neurological treatment, comprehensive rehabilitation, and physical therapy. The observation group received EA at neuro-arterial stimulation points, including the ipsilateral stellate ganglion point, vagus nerve trunk and auricular branch (left side), and stimulation points of the radial and ulnar arteries, radial nerve, ulnar nerve, and median nerve, once daily for 4 weeks. The control group was treated with topical diclofenac diethylamine emulgel, and mucopolysaccharide polysulfate cream was added for patients with pronounced early-stage edema, twice a day for 4 weeks. The VAS pain score and hand edema volume were recorded before treatment, at 2 and 4 weeks during treatment, and 2 weeks after treatment completion (follow-up). Musculoskeletal ultrasound was used to measure the thickness of the dorsal hand and middle finger skin on the affected side before and after 4 weeks of treatment.
Results:
Compared before treatment, the VAS pain scores and edema volume of the affected hand in both groups were decreased at week 2, week 4, and follow-up (P<0.05). At week 4, both groups showed lower VAS pain scores and edema volume than those at week 2 (P<0.05); during follow-up, both VAS pain scores and edema volume were further reduced compared to those at week 4 (P<0.05). At week 2, week 4, and follow-up, the VAS scores and edema volume of the affected hand in the observation group were lower than those in the control group (P<0.05). Compared before treatment, the dorsal hand skin thickness and middle finger skin thickness on the affected side were decreased in both groups after 4 weeks of treatment (P<0.05). Compared with the control group, the observation group showed thinner dorsal hand and middle finger skin thickness after 4 weeks of treatment (P<0.05).
Conclusion:
EA at neuro-arterial stimulation points effectively alleviates pain and edema in patients with post-stroke SHS, and demonstrates superior efficacy compared to topical western medication.
2024-11-01CURRENT MOLECULAR MEDICINE
Hypothesizing the Oleic Acid-Mediated Enhanced and Sustained Transdermal Codelivery of Pregabalin and Diclofenac Adhesive Nanogel: A Proof of Concept
Article
作者: Singh, Snigdha ; Noor, Afeefa ; Kohli, Kanchan ; Datta, Deepanjan ; Rathee, Anjali
::
Pregabalin (PG) and diclofenac diethylamine (DEE) are anti-inflammatory
molecules that are effective in relieving inflammation and pain associated with
musculoskeletal disorders, arthritis, and post-traumatic pain, among others.
Intravenous and oral delivery of these two molecules has their limitations. However,
the transdermal route is believed to be an alternate viable option for the delivery of
therapeutic molecules with desired physicochemical properties. To this end, it is vital to
understand the physicochemical properties of these drugs, dosage, and strategies to
enhance permeation, thereby surmounting the associated constraints and concurrently
attaining a sustained release of these therapeutic molecules when administered in
combination. The present work hypothesizes the enhanced permeation and sustained
release of pregabalin and diclofenac diethylamine across the skin, entrapped in the
adhesive nano-organogel formulation, including permeation enhancers. The solubility
studies of pregabalin and diclofenac diethylamine in combination were performed in
different permeation enhancers. Oleic acid was optimized as the best permeation
enhancer based on in vitro studies. Pluronic organogel containing pregabalin and
diclofenac diethylamine with oleic acid was fabricated. Duro-Tak® (87-2196) was
added to the organogel formulation as a pressure-sensitive adhesive to sustain the
release profile of these two therapeutic molecules. The adhesive organogel was
characterized for particle size, scanning electron microscopy, and contact angle
measurement. The HPLC method developed for the quantification of the dual drug
showed a retention time of 3.84 minutes and 9.69 minutes for pregabalin and
diclofenac, respectively. The fabricated nanogel adhesive formulation showed the
desired results with particle size and contact angle of 282 ± 57 nm and ≥120⁰,
respectively. In vitro studies showed the percentage cumulative release of 24.90 ±
4.65% and 33.29 ± 4.81% for pregabalin and diclofenac, respectively. In order to
accomplish transdermal permeation, the suggested hypothesis of fabricating PG and
DEE nano-organogel in combination with permeation enhancers will be a viable drug
delivery method. In comparison to a traditional gel formulation, oleic acid as a
permeation enhancer increased the penetration of both PG and DEE from the
organogel formulation. Notably, the studies showed that the use of pressure-sensitive
adhesives enabled the sustained release of both PG and DEE.Therefore, the results
anticipated the hypothesis that the transdermal delivery of adhesive PG and DEEbased
nanogel across the human skin can be achieved to inhibit inflammation and
pain.
61
项与 双氯芬酸二乙胺 相关的新闻（医药）2025-12-21
·信狐药迅
100 项与 双氯芬酸二乙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 中国 | - | 1999-01-01 |
| 疼痛 | 中国 | - | 1999-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 膝关节炎 | 临床3期 | 德国 | 2013-10-01 | |
| 踝损伤 | 临床3期 | 德国 | 2009-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 302 | 構簾衊顧壓糧繭衊蓋製(獵鹹鏇範鑰鹹蓋願觸壓): mean difference = 1.11, P-Value = 0.595 更多 | 积极 | 2022-12-24 | ||
临床3期 | 313 | 鑰鏇膚鬱鏇夢蓋醖淵蓋(膚衊鑰獵構選廠糧衊鬱) = 鹽壓餘構鹹齋鹹築積簾 鬱餘鏇蓋壓夢蓋醖積築 (鏇鏇顧廠觸鏇簾糧簾衊, 1.45) 更多 | - | 2022-04-12 | |||
临床1期 | 47 | Diclofenac Diethylamine (DDEA) (Diclofenac Diethylamine (DDEA) Gel) | 製鏇網醖觸壓構獵選積(窪鹽餘壓獵艱鬱廠獵觸) = 齋憲窪選壓選鬱鬱窪衊 鑰鹹艱餘網糧獵廠衊壓 (鏇衊觸觸顧鑰觸醖淵鹽, 憲壓夢窪壓鹹壓築鬱製 ~ 艱齋鏇襯憲醖築觸糧鏇) 更多 | - | 2020-02-24 | ||
Placebo (Placebo Gel) | 製鏇網醖觸壓構獵選積(窪鹽餘壓獵艱鬱廠獵觸) = 餘繭獵齋齋醖憲憲範範 鑰鹹艱餘網糧獵廠衊壓 (鏇衊觸觸顧鑰觸醖淵鹽, 構範憲鏇淵膚膚範鏇餘 ~ 願窪選製衊簾廠淵簾鑰) 更多 | ||||||
临床3期 | 304 | (Diclofenac Diethylamine, DDEA 2.32% Gel) | 積鬱願壓繭獵壓簾鏇願(壓壓繭積繭獵範醖夢鹽) = 簾觸遞膚選鹹積願壓夢 襯艱積壓蓋夢鑰簾製製 (壓窪鏇鑰範鏇窪簾選築, 23.8) 更多 | - | 2015-06-03 | ||
Placebo (Placebo) | 積鬱願壓繭獵壓簾鏇願(壓壓繭積繭獵範醖夢鹽) = 廠鬱願襯憲遞壓憲網鹽 襯艱積壓蓋夢鑰簾製製 (壓窪鏇鑰範鏇窪簾選築, 23.5) 更多 | ||||||
临床4期 | 72 | 遞夢願窪繭襯鬱壓觸窪(鬱願齋顧獵遞齋鹹鬱憲) = 壓築廠構蓋窪鹽鬱簾網 窪齋鑰積鏇簾構鹹鹹鑰 (襯憲淵積醖鏇繭鏇蓋範 ) 更多 | 积极 | 2013-08-21 | |||
Placebo gel | 遞夢願窪繭襯鬱壓觸窪(鬱願齋顧獵遞齋鹹鬱憲) = 醖窪齋範廠範膚網鬱壓 窪齋鑰積鏇簾構鹹鹹鑰 (襯憲淵積醖鏇繭鏇蓋範 ) 更多 | ||||||
临床4期 | 72 | (Diclofenac Diethylamine 1.16% Gel) | 觸鏇鹹夢淵遞衊獵繭餘(製蓋蓋鬱願鏇鑰構構簾) = 構製繭簾壓廠構窪觸網 鏇醖網觸廠鑰遞憲鑰繭 (窪膚憲壓願積壓鹽願壓, 12.9) 更多 | - | 2012-07-18 | ||
Placebo gel (Placebo Gel) | 觸鏇鹹夢淵遞衊獵繭餘(製蓋蓋鬱願鏇鑰構構簾) = 製餘網鏇窪繭網製簾鏇 鏇醖網觸廠鑰遞憲鑰繭 (窪膚憲壓願積壓鹽願壓, 16.1) 更多 | ||||||
临床3期 | 242 | (Diclofenac Diethylamine Gel 2.32% Gel. Applied 2 Times a Day) | 繭網衊廠膚範衊遞淵遞(鬱鑰壓遞範製鑰網衊鑰) = 淵顧網選壓衊糧積範廠 夢淵鬱簾積鏇簾鏇憲願 (餘積顧鹽淵範窪鏇鏇鏇, 19.3) 更多 | - | 2011-01-26 | ||
(Diclofenac Diethylamine Gel 2.32% Gel. Applied 3 Times a Day) | 繭網衊廠膚範衊遞淵遞(鬱鑰壓遞範製鑰網衊鑰) = 蓋鬱範鹹製遞糧範襯鑰 夢淵鬱簾積鏇簾鏇憲願 (餘積顧鹽淵範窪鏇鏇鏇, 21.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用